Latest revenue
$2.8M
as of 2026-03-31
Latest net income
$-7.0M
as of 2026-03-31
Net margin
-251.9%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $331.8M
- Enterprise value
- $331.8M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $15.37
- 52-wk low
- $3.43
- Beta
- —
- Shares out
- 50.0M
5-year trend
What this company does
Item 1. Business We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care. We are a Delaware company, incorporated in 2005. Our corporate headquarters is located in Saratoga, California. Currently, our GI-tract capsule endoscopy solution comprises our single-use CapsoCam capsule and the associated software, CapsoCloud and CapsoView. The CapsoCam capsule, with its panoramic view, acquires and stores video images in onboard memory…
AI summary unavailable — showing raw filing excerpt
Generated from CV's filing dated 2026-03-26
Key risks
Item 1A. Risk Factors You should carefully consider the risks and uncertainties described below, as well as the other information in this Annual Report and in our other public filings, including in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in our financial statements and the related notes appearing elsewhere in this Annual Report and in our other public filings, which could materially affect our business, financial condition or future results. The risks described below are not the only risks that we face. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or…
AI summary unavailable — showing raw filing excerpt
Generated from CV's filing dated 2026-03-26
Profitability
Gross margin
52.9%
2.4%Operating margin
-188.3%
11.1%Net margin
-186.8%
10.3%Return on equity
-190.9%
1342.6%Return on assets
-139.4%
17.7%Leverage
Debt / equity
0.37×
132.7%Debt / assets
27.0%
96.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $2.8M | +0.3% | $-7.0M | -30.8% | -251.9% |
Q4 2025 2025-12-31 | $3.9M | — | $-7.4M | — | -188.7% |
Q3 2025 2025-09-30 | $3.5M | +19.3% | $-7.9M | -36.7% | -223.9% |
Q2 2025 2025-06-30 | $3.3M | +16.6% | $-4.6M | +12.2% | -139.5% |
Q1 2025 2025-03-31 | $2.8M | — | $-5.4M | — | -193.1% |
Q3 2024 2024-09-30 | $3.0M | — | $-5.8M | — | -195.3% |
Q2 2024 2024-06-30 | $2.8M | — | $-5.3M | — | -185.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Electromedical & Electrotherapeutic Apparatus · SIC 3845
Your notes
Keep private notes on CV — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$83
Insider selling
$0
Net activity
+$83
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns CV
Institutional value
$20.9M
Total shares held
2.9M
Distinct holders
28
-4 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 1.3M | $9.5M | +1.0M (+407.7%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1.0M | $7.5M | — | New |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 164.4K | $1.2M | — | New |
| 4 | VANGUARD FIDUCIARY TRUST CO | 88.6K | $646.1K | — | New |
| 5 | UBS Group AG | 65.2K | $475.0K | +59.6K (+1066.2%) | Added |
| 6 | Bank of New York Mellon Corp | 49.3K | $359.4K | — | New |
| 7 | Nuveen, LLC | 33.1K | $241.3K | — | New |
| 8 | JANE STREET GROUP, LLC | 31.4K | $228.7K | — | New |
| 9 | DEUTSCHE BANK AG\ | 25.3K | $184.4K | +20.9K (+480.7%) | Added |
| 10 | RHUMBLINE ADVISERS | 13.1K | $95.7K | +9.7K (+286.0%) | Added |
| 11 | JPMORGAN CHASE & CO | 11.3K | $81.0K | +9.0K (+397.1%) | Added |
| 12 | Alaska Wealth Advisors | 11.1K | $80.9K | +0 (+0.0%) | No change |
| 13 | WELLS FARGO & COMPANY/MN | 10.2K | $74.7K | +4.0K (+63.0%) | Added |
| 14 | NEW YORK STATE COMMON RETIREMENT FUND | 7.1K | $51.9K | +0 (+0.0%) | No change |
| 15 | Police & Firemen's Retirement System of New Jersey | 7.0K | $50.7K | — | New |
| 16 | BNP PARIBAS FINANCIAL MARKETS | 6.1K | $44.5K | +3.9K (+176.3%) | Added |
| 17 | Vanguard Global Advisers, LLC | 2.5K | $18.5K | — | New |
| 18 | Legal & General Group Plc | 2.4K | $17.5K | +1.8K (+314.9%) | Added |
| 19 | Ameritas Investment Partners, Inc. | 2.3K | $16.6K | +1.8K (+379.8%) | Added |
| 20 | Russell Investments Group, Ltd. | 2.2K | $16.1K | +1.7K (+351.1%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once CV's latest filing finishes processing.